The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 I.c.v.-injected mice: Involvement of dopaminergic systems

Dayong Wang, Yukihiro Noda, Yuan Zhou, Akihiro Mouri, Hiroyuki Mizoguchi, Atsumi Nitta, Weiduo Chen, Toshitaka Nabeshima

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Galantamine, a drug for Alzheimer's disease, is a novel cholinergic agent with a dual mode of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors (nAChRs), as a result stimulates catecholamine neurotransmission. In the present study, we investigated whether galantamine exerts cognitive improving effects through the allosteric modulation of nAChR in the intracerebroventricular beta amyloid (Aβ) 25-35 -injected animal model of Alzheimer's disease. Galantamine (3 mg/kg p.o.) significantly increased the extracellular dopamine release in the hippocampus of saline- and Aβ 25-35 -injected mice. The effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nAChR antagonist. Aβ 25-35 -injected mice, compared with saline-injected mice, could not discriminate between new and familiar objects in the novel object recognition test and exhibited less freezing response in the fear-conditioning tasks, suggesting Aβ 25-35 induced cognitive impairment. Galantamine improved the Aβ 25-35 -induced cognitive impairment in the novel object recognition and fear-conditioning tasks. These improving effects of galantamine were blocked by the treatment with mecamylamine, SCH-23390, a dopamine-D1 receptor antagonist, and sulpiride, a dopamine-D2 receptor antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist. This study provides the first in vivo evidence that galantamine augments dopaminergic neurotransmission within the hippocampus through the allosteric potentiation of nAChRs. The improving-effects of galantamine on the Aβ 25-35 -induced cognitive impairment may be mediated through the activation of, at least in part, dopaminergic systems, and the enhancement of dopamine release may be one of multiple mechanisms underlying the therapeutic benefit of galantamine.

Original languageEnglish
Pages (from-to)1261-1271
Number of pages11
JournalNeuropsychopharmacology
Volume32
Issue number6
DOIs
Publication statusPublished - 01-06-2007
Externally publishedYes

Fingerprint

Galantamine
Nicotinic Receptors
Mecamylamine
Dopamine
Synaptic Transmission
Fear
Hippocampus
Alzheimer Disease
amyloid beta-protein (25-35)
Cognitive Dysfunction
Dopamine D1 Receptors
Sulpiride
Scopolamine Hydrobromide
Dopamine Antagonists
Cholinergic Antagonists
Muscarinic Receptors
Acetylcholinesterase
Nicotine
Cholinergic Agents
Freezing

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health

Cite this

@article{e3527d0d0fc24cccaf07ec9d3bcc0ab6,
title = "The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 I.c.v.-injected mice: Involvement of dopaminergic systems",
abstract = "Galantamine, a drug for Alzheimer's disease, is a novel cholinergic agent with a dual mode of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors (nAChRs), as a result stimulates catecholamine neurotransmission. In the present study, we investigated whether galantamine exerts cognitive improving effects through the allosteric modulation of nAChR in the intracerebroventricular beta amyloid (Aβ) 25-35 -injected animal model of Alzheimer's disease. Galantamine (3 mg/kg p.o.) significantly increased the extracellular dopamine release in the hippocampus of saline- and Aβ 25-35 -injected mice. The effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nAChR antagonist. Aβ 25-35 -injected mice, compared with saline-injected mice, could not discriminate between new and familiar objects in the novel object recognition test and exhibited less freezing response in the fear-conditioning tasks, suggesting Aβ 25-35 induced cognitive impairment. Galantamine improved the Aβ 25-35 -induced cognitive impairment in the novel object recognition and fear-conditioning tasks. These improving effects of galantamine were blocked by the treatment with mecamylamine, SCH-23390, a dopamine-D1 receptor antagonist, and sulpiride, a dopamine-D2 receptor antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist. This study provides the first in vivo evidence that galantamine augments dopaminergic neurotransmission within the hippocampus through the allosteric potentiation of nAChRs. The improving-effects of galantamine on the Aβ 25-35 -induced cognitive impairment may be mediated through the activation of, at least in part, dopaminergic systems, and the enhancement of dopamine release may be one of multiple mechanisms underlying the therapeutic benefit of galantamine.",
author = "Dayong Wang and Yukihiro Noda and Yuan Zhou and Akihiro Mouri and Hiroyuki Mizoguchi and Atsumi Nitta and Weiduo Chen and Toshitaka Nabeshima",
year = "2007",
month = "6",
day = "1",
doi = "10.1038/sj.npp.1301256",
language = "English",
volume = "32",
pages = "1261--1271",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "6",

}

The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 I.c.v.-injected mice : Involvement of dopaminergic systems. / Wang, Dayong; Noda, Yukihiro; Zhou, Yuan; Mouri, Akihiro; Mizoguchi, Hiroyuki; Nitta, Atsumi; Chen, Weiduo; Nabeshima, Toshitaka.

In: Neuropsychopharmacology, Vol. 32, No. 6, 01.06.2007, p. 1261-1271.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 I.c.v.-injected mice

T2 - Involvement of dopaminergic systems

AU - Wang, Dayong

AU - Noda, Yukihiro

AU - Zhou, Yuan

AU - Mouri, Akihiro

AU - Mizoguchi, Hiroyuki

AU - Nitta, Atsumi

AU - Chen, Weiduo

AU - Nabeshima, Toshitaka

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Galantamine, a drug for Alzheimer's disease, is a novel cholinergic agent with a dual mode of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors (nAChRs), as a result stimulates catecholamine neurotransmission. In the present study, we investigated whether galantamine exerts cognitive improving effects through the allosteric modulation of nAChR in the intracerebroventricular beta amyloid (Aβ) 25-35 -injected animal model of Alzheimer's disease. Galantamine (3 mg/kg p.o.) significantly increased the extracellular dopamine release in the hippocampus of saline- and Aβ 25-35 -injected mice. The effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nAChR antagonist. Aβ 25-35 -injected mice, compared with saline-injected mice, could not discriminate between new and familiar objects in the novel object recognition test and exhibited less freezing response in the fear-conditioning tasks, suggesting Aβ 25-35 induced cognitive impairment. Galantamine improved the Aβ 25-35 -induced cognitive impairment in the novel object recognition and fear-conditioning tasks. These improving effects of galantamine were blocked by the treatment with mecamylamine, SCH-23390, a dopamine-D1 receptor antagonist, and sulpiride, a dopamine-D2 receptor antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist. This study provides the first in vivo evidence that galantamine augments dopaminergic neurotransmission within the hippocampus through the allosteric potentiation of nAChRs. The improving-effects of galantamine on the Aβ 25-35 -induced cognitive impairment may be mediated through the activation of, at least in part, dopaminergic systems, and the enhancement of dopamine release may be one of multiple mechanisms underlying the therapeutic benefit of galantamine.

AB - Galantamine, a drug for Alzheimer's disease, is a novel cholinergic agent with a dual mode of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors (nAChRs), as a result stimulates catecholamine neurotransmission. In the present study, we investigated whether galantamine exerts cognitive improving effects through the allosteric modulation of nAChR in the intracerebroventricular beta amyloid (Aβ) 25-35 -injected animal model of Alzheimer's disease. Galantamine (3 mg/kg p.o.) significantly increased the extracellular dopamine release in the hippocampus of saline- and Aβ 25-35 -injected mice. The effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nAChR antagonist. Aβ 25-35 -injected mice, compared with saline-injected mice, could not discriminate between new and familiar objects in the novel object recognition test and exhibited less freezing response in the fear-conditioning tasks, suggesting Aβ 25-35 induced cognitive impairment. Galantamine improved the Aβ 25-35 -induced cognitive impairment in the novel object recognition and fear-conditioning tasks. These improving effects of galantamine were blocked by the treatment with mecamylamine, SCH-23390, a dopamine-D1 receptor antagonist, and sulpiride, a dopamine-D2 receptor antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist. This study provides the first in vivo evidence that galantamine augments dopaminergic neurotransmission within the hippocampus through the allosteric potentiation of nAChRs. The improving-effects of galantamine on the Aβ 25-35 -induced cognitive impairment may be mediated through the activation of, at least in part, dopaminergic systems, and the enhancement of dopamine release may be one of multiple mechanisms underlying the therapeutic benefit of galantamine.

UR - http://www.scopus.com/inward/record.url?scp=34249090813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249090813&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301256

DO - 10.1038/sj.npp.1301256

M3 - Article

C2 - 17133263

AN - SCOPUS:34249090813

VL - 32

SP - 1261

EP - 1271

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 6

ER -